Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/ΔM2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age
Brief Summary: The purpose of this study was to evaluate the safety, infectivity, and immunogenicity of a single dose of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine in RSV-seronegative infants and children 6 to 24 months of age.

This study was a companion study to CIR 313.


Options:
A: Arm Label: GSK3389245A_LD GROUP; Type: EXPERIMENTAL; Interventions: Biological: GSK3389245A_LD GROUP | Arm Label: GSK3389245A_HD GROUP; Type: EXPERIMENTAL; Interventions: Biological: GSK3389245A_HD GROUP | Arm Label: Bexsero Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bexsero | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: GSK3389245A_LD GROUP; Assigned to Arm(s): GSK3389245A_LD GROUP | Intervention Type: BIOLOGICAL; Name: GSK3389245A_HD GROUP; Assigned to Arm(s): GSK3389245A_HD GROUP | Intervention Type: BIOLOGICAL; Name: Bexsero; Assigned to Arm(s): Bexsero Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: EDP-938 Arm A; Type: EXPERIMENTAL; Interventions: Drug: EDP-938 Dose 1 | Arm Label: EDP-938 Arm B; Type: EXPERIMENTAL; Interventions: Drug: EDP-938 Dose 2 | Arm Label: Placebo Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: EDP-938 Arm D; Type: EXPERIMENTAL; Interventions: Drug: EDP-938 Dose 3 | Arm Label: EDP-938 Arm E; Type: EXPERIMENTAL; Interventions: Drug: EDP-938 Dose 4 | Arm Label: Placebo Arm F; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: EDP-938 Dose 1; Assigned to Arm(s): EDP-938 Arm A | Intervention Type: DRUG; Name: EDP-938 Dose 2; Assigned to Arm(s): EDP-938 Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm C | Intervention Type: DRUG; Name: EDP-938 Dose 3; Assigned to Arm(s): EDP-938 Arm D | Intervention Type: DRUG; Name: EDP-938 Dose 4; Assigned to Arm(s): EDP-938 Arm E | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm F
C: Arm Label: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine; Type: EXPERIMENTAL; Interventions: Biological: D46/NS2/N/ΔM2-2-HindIII | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: D46/NS2/N/ΔM2-2-HindIII; Assigned to Arm(s): RSV D46/NS2/N/ΔM2-2-HindIII Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo + Inactivated Influenza Vaccine (IIV); Type: ACTIVE_COMPARATOR; Interventions: Biological: IIV, Other: Placebo | Arm Label: MEDI7510 + IIV; Type: EXPERIMENTAL; Interventions: Biological: MEDI7510, Biological: IIV | Intervention Type: BIOLOGICAL; Name: MEDI7510; Assigned to Arm(s): MEDI7510 + IIV | Intervention Type: BIOLOGICAL; Name: IIV; Assigned to Arm(s): MEDI7510 + IIV, Placebo + Inactivated Influenza Vaccine (IIV) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Inactivated Influenza Vaccine (IIV)

Answer: C